摘要
目的:观察补肾益髓胶囊对缓解期视神经脊髓炎(NMO)患者上皮嗜中性粒细胞活化肽78(ENA 78)及相关细胞因子白介素-1β(IL-1β)与肿瘤坏死因子-α(TNF-α)表达水平的影响,探讨补肾益髓胶囊调节缓解期NMO患者中性粒细胞活性的作用机制。方法:评估25例缓解期NMO患者规律使用补肾益髓胶囊治疗3个月前后的扩展残疾状态量表(EDSS)评分及中医症状评分,使用人高敏感性多细胞因子试剂盒检测治疗前后血浆ENA 78、IL-1β和TNF-α表达水平。结果:经补肾益髓胶囊干预3个月后,患者中医症状评分较前降低(P<0.01),EDSS评分差异无统计学意义,血浆中细胞因子ENA 78、IL-1β、TNF-α表达量较治疗前均降低(P<0.01,P<0.05)。结论:补肾益髓胶囊可以降低缓解期NMO患者的中医症状评分,其部分机制可能是通过降低缓解期NMO患者外周血IL-1β与TNF-α水平进而降低ENA 78的表达水平,减轻由ENA 78介导的中性粒细胞炎性反应。
Objective: To observe the effects of Bushen Yisui Capsule on epithelial neutrophil activating peptide 78(ENA 78), interleukin(IL) 1β and tumor necrosis factor α(TNF-α) in neuromyelitis optica(NMO) patients during remission and investigate the mechanism of Bushen Yisui Capsule in regulating neutrophil activity of NMO patients during the remission.Methods: Expanded disability status scale(EDSS) and traditional Chinese medicine symptoms(TCMS) scores were used to evaluate 25 NMO patients during remission treated with Bushen Yisui Capsule for 3 months. The plasma levels of ENA 78, IL-1β and TNF-α were detected by human multiplex high sensitive assay before and after treatment with Bushen Yisui Capsule,respectively. Results: The TCMS scores were reduced by Bushen Yisui Capsule treatment(P<0.01), but there was no significant difference on EDSS scores between before and after treatment with Bushen Yisui Capsule. The levels of ENA 78, IL-1βand TNF-α were significantly decreased by Bushen Yisui Capsule treatment in NMO patients during remission(P<0.01, P<0.05).Conclusion: Bushen Yisui Capsule could reduce TCMS scores of NMO patients during remission, part of the mechanisms might be to reduce pro-inflammatory cytokines such as IL-1β and TNF-α, which could inhibit ENA 78 expression, then to alleviate neutrophil infiltration induced by ENA78.
引文
[1]Lucchinetti C F,Mandler R N,McGavern D,et al.A role for humoralmechanisms in the pathogenesis of Devic’s neuromyelitis optica.Brain,2002,125(Pt 7):1450-1461
[2]Asgari N,Owens T,Fr?kiaer J,et al.Neuromyelitis optica(NMO)-an autoimmune disease of the central nervous system(CNS).ActaNeurol Scand,2011,123(6):369-384
[3]Shiee N,Bazin P L,Zackowski K M,et al.Revisiting brain atrophyand its relationship to disability in multiple sclerosis.PLoS One,2012,7(5):e37049
[4]Franciotta D,Gastaldi M,Sala A,et al.Diagnostics of theneuromyelitis optica spectrum disorders(NMOSD).Neurol Sci,2017,38(Suppl 2):231-236
[5]Wingerchuk D M,Lennon V A,Lucchinetti C F,et al.The spectrumof neuromyelitis optica.Lancet Neurol,2007,6(9):805-815
[6]Jarius S,Wildemann B.AQP4 antibodies in neuromyelitisoptica:diagnostic and pathogenetic relevance.Nat Rev Neurol,2010,6(7):383-392
[7]Weinshenker B G,Wingerchuk D M.Neuromyelitis spectrumdisorders.Mayo Clin Proc,2017,92(4):663-679
[8]樊永平,胡蕊,鲍显慧,等.63例视神经脊髓炎患者临床特点和中医证型分布.中国中西医结合杂志,2013,33(3):322-325
[9]吴畏,樊永平,胡蕊.多发性硬化与视神经脊髓炎的临床特点和中医证候比较研究.北京中医药,2013,32(7):506-509
[10]杨涛.补肾化痰活血法对视神经脊髓炎谱系疾病临床疗效及免疫功能的影响.北京:首都医科大学,2017
[11]王苏.补肾益髓胶囊对视神经脊髓炎缓解期临床疗效及体液免疫功能的影响.北京:北京中医药大学,2015
[12]Meyer-Moock S,Feng Y S,Maeurer M,et al.Systematic literaturereview and validity evaluation of the Expanded DisabilityStatus Scale(EDSS)and the Multiple Sclerosis FunctionalComposite(MSFC)in patients with multiple sclerosis.BMC Neurol,2014,14:58
[13]樊永平,王平,张星虎,等.二黄方治疗多发性硬化急性发作的机制研究.中华中医药杂志,2007,22(1):25-29
[14]Wingerchuk D M,Lennon V A,Pittock S J,et al.Revised diagnosticcriteria for neuromyelitis optica.Neurology,2006,66(10):1485-1489
[15]Saadoun S,Waters P,MacDonald C,et al.Neutrophil proteaseinhibition reduces neuromyelitis optica-immunoglobulin G-induceddamage in mouse brain.Ann Neurol,2012,71(3):323-333
[16]Papadopoulos M C,Bennett J L,Verkman A S.Treatment ofneuromyelitis optica:state-of-the-art and emerging therapies.NatRev Neurol,2014,10(9):493-506
[17]Zhang H,Bennett JnL,Verkman AnS.Ex vivo spinal cord slicemodel of neuromyelitis optica reveals novel immunopathogenicmechanisms.Ann Neurol,2011,70(6):943-954
[18]Jarius S,Paul F,Franciotta D,et al.Cerebrospinal fluid findings inaquaporin-4 antibody positive neuromyelitis optica:results from211 lumbar punctures.J Neurol Sci,2011,306(1-2):82-90
[19]Sanz M J,Kubes P.Neutrophil-active chemokines in in vivo imagingof neutrophil trafficking.Eur J Immunol,2012,42(2):278-283
[20]Smit J J,Lukacs N W.A closer look at chemokines and their role inasthmatic responses.Eur J Pharmacol,2006,533(1-3):277-288
[21]Zwijnenburg P J,de Bie H M,Roord J J,et al.Chemotactic activity ofCXCL5 in cerebrospinal fluid of children with bacterial meningitis.J Neuroimmunol,2003,145(1-2):148-153
[22]Kawamura M,Toiyama Y,Tanaka K,et al.CXCL5,a promoterof cell proliferation,migration and invasion,is a novel serumprognostic marker in patients with colorectal cancer.Eur J Cancer,2012,48(14):2244-2251
[23]Mostafa G A,Al-Ayadhi L Y.The possible link between elevatedserum levels of epithelial cell-derived neutrophil-activatingpeptide-78(ENA-78/CXCL5)and autoimmunity in autisticchildren.Behav Brain Funct,2015,11:11
[24]Rowland K J,Diaz-Miron J,Guo J,et al.CXCL5 is required forangiogenesis,but not structural adaptation after small bowelresection.J Pediatr Surg,2014,49(6):976-980
[25]Zheng J,Zhu X,Zhang J.CXCL5 knockdown expression inhibitshuman bladder cancer T24 cells proliferation and migration.Biochem Biophys Res Commun,2014,446(1):18-24
[26]Zineh I,Aquilante C L,Langaee T Y,et al.CXCL5 genepolymorphisms are related to systemic concentrations andleukocyte production of epithelial neutrophil-activating peptide(ENA-78).Cytokine,2006,33(5):258-263
[27]Zineh I,Luo X,Welder G J,et al.Modulatory effects of atorvastatinon endothelial cell-derived chemokines,cytokines,and angiogenicfactors.Pharmacotherapy,2006,26(3):333-340
[28]Yang T,Wang S,Zheng Q,et al.Increased plasma levels of epithelialneutrophil-activating peptide 78/CXCL5 during the remission ofNeuromyelitis optica.BMC Neurol,2016,16:96
[29]Guha D,Klamar C R,Reinhart T,et al.Transcriptional regulationof CXCL5 in HIV-1-infected macrophages and its functionalconsequences on CNS pathology.J Interferon Cytokine Res,2015,35(5):373-384
[30]Chandrasekar B,Melby P C,Sarau H M,et al.Chemokine-cytokinecross-talk.The ELR+CXC chemokine LIX(CXCL5)amplifiesa proinflammatory cytokine response via a phosphatidylinositol3-kinase-NF-kappa B pathway.J Biol Chem,2003,278(7):4675-4686
[31]Duchene J,Lecomte F,Ahmed S,et al.A novel inflammatory pathwayinvolved in leukocyte recruitment:role for the kinin B1 receptor andthe chemokine CXCL5.J Immunol,2007,179(7):4849-4856
